Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/27/2007WO2007061625A3 A therapeutic composition containing an organosilane quaternary compound and hydrogen peroxide for treating skin disorders
09/27/2007WO2007055942A3 Substituted nicotinamide compounds
09/27/2007WO2007055388A3 Calcium receptor activator
09/27/2007WO2007054911A8 Compositions useful for recovering original trophism and pigmentation, and for stimulating growth of the integumentary apparatus, uses and products thereof .
09/27/2007WO2007054565A3 New stabilized galenic formulations comprising lansoprazole and their preparation
09/27/2007WO2007049088A8 Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues
09/27/2007WO2007047907A3 Dek protein compositions and methods of using the same
09/27/2007WO2007047646A3 Substituted dihydro-isoindolones useful in treating kinase disorders
09/27/2007WO2007044357A3 Formulations of aica riboside
09/27/2007WO2007044325A3 Apoe4 domain interaction inhibitors and methods of use thereof
09/27/2007WO2007044296A3 Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
09/27/2007WO2007041282A3 Methods and compositions for treatment of cystic fibrosis
09/27/2007WO2007038496A3 Synthesis of fatty alcohol esters of hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers
09/27/2007WO2007026265A3 Use of enoxaparin for performimg percutaneous coronary intervention
09/27/2007WO2007026125A3 Anti-viral topical gel formulations containing a diuretic such as furosemide and/or a cardiac glycoside such as digoxin
09/27/2007WO2007025092A3 Stabilized and preserved ketotifen ophthalmic compositions
09/27/2007WO2007025009A3 Indenoisoquinolinone analogs and methods of use thereof
09/27/2007WO2007024741A3 Methods for treatment of thiol-containing compound deficient conditions
09/27/2007WO2007023389A3 Polymorphic forms of 3-amino-1-propanesulfonic acid
09/27/2007WO2007022408A3 Combination methods of saha and targretin for treating cancer
09/27/2007WO2007022225A3 Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
09/27/2007WO2007021941A3 Inhibitors of voltage-gated sodium channels
09/27/2007WO2007017331A3 Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
09/27/2007WO2007012075A3 Preparation of montelukast
09/27/2007WO2007012057A3 Vegetation water composition for treatment of inflammatory skin conditions
09/27/2007WO2007005962A3 Combinations of eszopiclone and an antidepressant
09/27/2007WO2007005780A3 Compositions and methods for treating gastrointestinal hypomotility and associated disorders
09/27/2007WO2007003200A3 High yield synthesis methods for producing organic salts of strontium
09/27/2007WO2007000764A3 Compositions and methods for enhancement of sexual function
09/27/2007WO2006124862A3 Methods for the treatment of ocular and neurodegenerative conditions in a mammal
09/27/2007WO2006105850A8 Acyl hydrazides as kinase inhibitors, in particular for sgk
09/27/2007WO2006102451A3 Amino acid composition for improving glucose tolerance
09/27/2007WO2006096444A3 Chemical compounds
09/27/2007WO2006088491A3 Methods and compositions related to the modulation of intercellular junctions
09/27/2007WO2006076317A9 Aminophenyl derivatives as selective androgen receptor modulators
09/27/2007WO2006072965A3 Sucrose-6-ester chlorination by co-addition of chlorination reagent.
09/27/2007WO2006017318A3 Methods for treating cancer using agents that inhibit wnt16 signaling
09/27/2007WO2005112952A3 Geldanamycin compounds and method of use
09/27/2007WO2005089380A3 Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
09/27/2007WO2005018623A3 Parenteral and oral formulations of benzimidazoles
09/27/2007US20070226815 Protein with immunomodulatory activity, antiviral activity, and antitumor activity encoded by a IFN-alpha upregulated gene; treating any Type 1 interferon treatable disease including cancer; determining if a patient will respond to interferon treatment; transgenic animals, primers, probes, antibodies
09/27/2007US20070225727 Transparent Tissue-Visualizng Preparation
09/27/2007US20070225506 Bactericides; 2-[(1R)-1-methyl-2-trityl-2,3-dihydro-1H-5-isoindolyl]-1,3,6,2-dioxazaborocane.
09/27/2007US20070225495 N4-(2,2-Dimethyl-3-oxo-4H-5-pyrid[1,4]oxazin-6-yl)-N2-(3-chloro-4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for IgE (Fc epsilon RI) and IgG (Fc gamma RI) antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis
09/27/2007US20070225492 3,6-Diazabicyclo[3.1.1]Heptane Derivatives with Analgesic Activity
09/27/2007US20070225379 Analgesic, Parkinson or Alzheimer drug in a solvent system containing a monoalkyl ether of diethylene glycol, a glycol, and a mixture of a C2 to C4 alcohol and water; inhibits crystallization and transfer to clothing, improves and modulates bioavailability within skin layers; nonocclusive, semi-solid
09/27/2007US20070225377 Bridged Ring Structures as Pharmaceutical Agents
09/27/2007US20070225376 Medicinal Agent
09/27/2007US20070225375 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
09/27/2007US20070225374 Hydroxypropyl Amides for the Treatment of Alzheimer's Disease
09/27/2007US20070225373 Zn2Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase
09/27/2007US20070225371 Dermatological composition containing alkyl ureas
09/27/2007US20070225370 Nutritional Compositions and Methods
09/27/2007US20070225369 Ophthalmic composition for treating tear dysfunction
09/27/2007US20070225368 Therapy for Multiple Sclerosis
09/27/2007US20070225367 Composition for beneficially influencing Alzheimer's disease and/or for Alzheimer's prophylaxis
09/27/2007US20070225366 Levodopa prodrug mesylate, compositions thereof, and uses thereof
09/27/2007US20070225365 Cetp Inhibitors
09/27/2007US20070225364 Use of bismuth subgallate and borneol in treating melanoma
09/27/2007US20070225363 Methods and Agents for Inhibiting Dynamin-Dependent Endocytosis
09/27/2007US20070225362 Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
09/27/2007US20070225361 Dimeric compounds and their use as anti-viral agents
09/27/2007US20070225360 Anti-aging composition containing phloretin
09/27/2007US20070225359 Dimeric compounds and their use as anti-viral agents
09/27/2007US20070225358 Dimeric compounds and thier use as anti-viral agents
09/27/2007US20070225357 Formulation for Stimulating Hair Growth
09/27/2007US20070225356 Preventive and/or Therapeutic Agent for Chronic Sinusitis
09/27/2007US20070225355 Dietary Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species
09/27/2007US20070225354 Use of dihydrolipoamide for enhancing physical performance
09/27/2007US20070225353 Process for Forming Amorphous Atorvastatin
09/27/2007US20070225352 methyl-[3-(2-nitro-phenylsulfanyl)-1-pyridin-2-ylmethyl-1H-indol-6-yl]-amine, possessing androgenic activity are useful in androgen-related treatments such as male hypogonadism, male and female hormone replacement therapy and male contraception
09/27/2007US20070225351 Methods and compositions for controlling body weight and appetite
09/27/2007US20070225350 Compositions and methods for treating neoplastic diseases
09/27/2007US20070225349 Substituted 4-(Indazol-3-yl)phenols
09/27/2007US20070225348 Amino acid composition for improving glucose tolerance
09/27/2007US20070225346 Crystalline Forms
09/27/2007US20070225345 Therapeutic Substituted Cyclopentanones
09/27/2007US20070225344 Sulfonamide derivatives to treat infection with hepatitis C virus
09/27/2007US20070225343 Pharmaceutical latrunculin formulations
09/27/2007US20070225342 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
09/27/2007US20070225341 Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor
09/27/2007US20070225340 Phenyl Compounds And Their Use In The Treatment Of Conditions Mediated By The Action Of Pge2 At The Ep1 Receptor
09/27/2007US20070225339 Compositions and methods for treating rheumatoid arthritis
09/27/2007US20070225337 Novel Co-Precipitate of Amorphous Rosiglitazone
09/27/2007US20070225336 Anthropodicidal anthranilamides
09/27/2007US20070225335 Pyrazole Derivatives for Treating Condit Ions Mediated by Activation of the Adeno Sine A2B or A3 Receptor
09/27/2007US20070225334 Methods for treating cognitive and other disorders
09/27/2007US20070225332 Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
09/27/2007US20070225331 4,4-Disubstituted piperidines, and methods of use thereof
09/27/2007US20070225330 Use of certain phenyl-naphthyl compounds that do not have significant affinity to er alpha or er beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis
09/27/2007US20070225329 Aryl aniline beta2 adrenergic receptor agonists
09/27/2007US20070225328 Synthetic nacre
09/27/2007US20070225327 3-Methyl-2-[4'-(pyridin-3-ylmethoxymethyl)-biphenyl-4-sulfonylamino]-butyric acid; metalloproteinase inhibitors; arthritis, macular degeneration, graft versus host disease, cancer, osteoarthritis
09/27/2007US20070225326 Useful for isolation and purification of the montelukast acid before its conversion to montelukast sodium
09/27/2007US20070225324 e.g. N-[2-(2-Hydroxy-ethyl)-1-oxo-1,2-dihydro-isoquinolin-5-yl]-benzamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction
09/27/2007US20070225323 Substituted 4-phenyltetrahyrdoisoquinolines, pharmaceutical compositions thereof, methods for their preparation and therapeutic use
09/27/2007US20070225322 Compositions and methods for treating middle-of-the night insomnia
09/27/2007US20070225321 2,4-pyrimidinediamine compounds and their uses
09/27/2007US20070225320 Process for preparing clopidogrel
09/27/2007US20070225319 Piperidinyl indole and tetrohydropyridinyl indole derivatives and methods of their use